Evidence map›Paper›PMID 11891193›Full record

ArticleThe American journal of pathology2002

Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway.

Susan C Abraham, Tsung-Teh Wu, Ralph H Hruban, Jae-Hyuk Lee, Charles J Yeo, Kevin Conlon, Murray Brennan, John L Cameron, David S Klimstra

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 2 syntheses or guidelines pooled it, 276 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Review
  5. The oncogenome of the domestic cat.Science (New York, N.Y.) · 2026
    Article
  6. Article
  7. Differential diagnosis and predictive markers of pancreatic neuroendocrine tumours (PanNET).Virchows Archiv : an international journal of pathology · 2026
    Review
  8. Article
  9. Metastatic pancreatic acinar cell carcinoma withJournal of gastrointestinal oncology · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Susan C AbrahamDepartment of Pathology, Division of GI/LiverPathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196, USA. sabraham@jhmi.edu
Tsung-Teh Wu
Ralph H Hruban
Jae-Hyuk Lee
Charles J Yeo
Kevin Conlon
Murray Brennan
John L Cameron
David S Klimstra
Johns Hopkins University · USMemorial Sloan Kettering Cancer Center · USJohns Hopkins Medicine · USOhio Gastroenterology and Liver Institute · US

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
NCI NIH HHS P50 CA062924NCI NIH HHS P50-CA62924
6 · The paper itself

Abstract

Acinar cell carcinomas (ACCs) are rare malignant tumors of the exocrine pancreas. The specific molecular alterations that characterize ACCs have not yet been elucidated. ACCs are morphologically and genetically distinct from the more common pancreatic ductal adenocarcinomas. Instead, the morphological, immunohistochemical, and clinical features of ACCs overlap with those of another rare pancreatic neoplasm, pancreatoblastoma. We have recently demonstrated a high frequency of allelic loss on chromosome arm 11p and mutations in the APC/beta-catenin pathway in pancreatoblastomas, suggesting that similar alterations might also play a role in the pathogenesis of some ACCs. We analyzed a series of 21 ACCs for somatic alterations in the APC/beta-catenin pathway and for allelic loss on chromosome 11p. In addition, we evaluated the ACCs for alterations in p53 and Dpc4 expression using immunohistochemistry, and for microsatellite instability (MSI) using polymerase chain amplification of a panel of microsatellite markers. Allelic loss on chromosome 11p was the most common genetic alteration in ACCs, present in 50% (6 of 12 informative cases). Molecular alterations in the APC/beta-catenin pathway were detected in 23.5% (4 of 17) of the carcinomas, including one ACC with an activating mutation of the beta-catenin oncogene and three ACCs with truncating APC mutations. One ACC (1 of 13, 7.6%) showed allelic shifts in four of the five markers tested (MSI-high), two (15.4%) showed an allelic shift in only one of the five markers tested (MSI-low), and no shifts were detected in the remaining 10 cases. The MSI-high ACC showed medullary histological features. In contrast, no loss of Dpc4 protein expression or p53 accumulation was detected. These results indicate that ACCs are genetically distinct from pancreatic ductal adenocarcinomas, but some cases contain genetic alterations common to histologically similar pancreatoblastomas.

Indexed as

Chromosomes, Human, Pair 11Loss of HeterozygosityTrans-ActivatorsAdenomatous Polyposis Coli ProteinAdolescentAdultAgedbeta CateninCarcinoma, Acinar CellChild, PreschoolChromosomes, Human, Pair 5Cytoskeletal ProteinsFemaleGenes, Tumor SuppressorHumansImmunohistochemistryAdenomatous Polyposis Coli Proteinbeta CateninCTNNB1 protein, humanCytoskeletal ProteinsTrans-Activators

Identifiers

PMID11891193
PMCPMC1867188
OpenAlexW1995851961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.